Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi

Journal of Medical Virology

Volumn 84, Issue 10, 2012, Pages 1553-1557

  Galluzzo, Clementina ^a   Liotta, Giuseppe ^b,c   Andreotti, Mauro ^a   Luhanga, Richard ^d   Jere, Haswell ^d   Mancinelli, Sandro ^b,c   Maulidi, Martin ^d   Sagno, Jean Baptiste ^d   Pirillo, Maria ^a   Erba, Fulvio ^b,c   Amici, Roberta ^a   Ceffa, Susanna ^c   Marazzi, Maria Cristina ^c,e   Vella, Stefano ^a   Palombi, Leonardo ^b,c   Giuliano, Marina ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c DREAM Program   (Italy)

^d DREAM Program   (Malawi)

^e LUMSA UNIVERSITY   (Italy)

Author keywords

Africa; Drug resistance; HBV; HIV; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOASSAY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; GESTATION PERIOD; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIVER DISEASE; MALAWI; PREGNANT WOMAN; VIRUS MUTATION; WILD TYPE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MALAWI; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84865538152     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23365     Document Type: Article

References (19)

1. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. 1999. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30:1302-1306.
2. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J. 2003. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 17:1649-1657.
3. Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, Neuhaus J, Puoti M, Klein MB, Mocroft A, Clotet B, Lundgren JD. 2010. Frequent hepatitis B virus (HBV) rebound among HIV -HBV coinfected patients following antiretroviral therapy interruption in the SMART study. AIDS 24:857-865.
4. Hoffmann C, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, Fielding KL, Thio CL. 2008. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 47:1479-1485.
5. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, Sankalé JL, Ekong E, Murphy R, Kanki P, Thio CL. 2009. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 49:1268-1273.
6. Joint United Nations Program on HIV/AIDS. 2010. Global Report: UNAIDS report on the global AIDS epidemic.
7. Kobayashi S, Ide T, Sata M. 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 37:259-265.
8. Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D. 2011. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat 18:e29-e39.
9. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
10. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. 2006. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20:863-870.
11. Mendes-Correa MC, Pinho JRR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE. 2010. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. J Med Virol 82:1481-1488.
12. Modi A, Feld J. 2007. Viral hepatitis and HIV in Africa. AIDS Rev 9:25-39.
13. Ramos B, Nunez M, Martin-Carbonero L, Sheldon J, Rios P, Labarga P, Romero M, Barreiro P, García-Samaniego J, Soriano V. 2007. Hepatitis B genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-co-infected patients. J Acquir Immune Defic Syndr 44:557-561.
14. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. 2007. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 79:1650-1654.
15. Soriano V, Rivas P, Nunez M. 2008. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis 47:1486-1489.
16. Sugauchi F, Orito E, Kato H, Suzuki S, Kawakita S, Sakamoto Y, Fukushima K, Akiba T, Yoshihara N, Ueda R, Mizokami M. 2003. Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus. J Med Virol 69:33-40.
17. Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spanò A, Perno CF. 2010. Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. Dig Liv Dis 42:902-907.
18. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. 2006. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 166:1632-1641.
19. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Available from: http://www.who.int/HIV/pub/arv/adult2010/en/